• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Systemic Lupus Erythematosus - Pipeline Review, H2 2012 Product Image

Systemic Lupus Erythematosus - Pipeline Review, H2 2012

  • ID: 2233945
  • August 2012
  • 207 pages
  • Global Markets Direct

Systemic Lupus Erythematosus – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Systemic Lupus Erythematosus - Pipeline Review, H2 2012', provides an overview of the Systemic Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Systemic Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus. 'Systemic Lupus Erythematosus - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Systemic Lupus Erythematosus.
- A review of the Systemic READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Systemic Lupus Erythematosus Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Systemic Lupus Erythematosus 10
Systemic Lupus Erythematosus Therapeutics under Development by Companies 12
Systemic Lupus Erythematosus Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Systemic Lupus Erythematosus Therapeutics – Products under Development by Companies 23
Systemic Lupus Erythematosus Therapeutics – Products under Investigation by Universities/Institutes 27
Companies Involved in Systemic Lupus Erythematosus Therapeutics Development 28
Johnson & Johnson 28
F. Hoffmann-La Roche Ltd. 29
Amgen Inc. 30
Eli Lilly and Company 31
GlaxoSmithKline plc 32
Genentech, Inc. 33
MedImmune LLC 34
Biotest AG 35
AbGenomics International, Inc. 36
Human Genome Sciences, Inc. 37
Pfizer Inc. 38
Rigel Pharmaceuticals, Inc. 39
Teva Pharmaceutical Industries Limited 40
UCB Group 41
Onyx Pharmaceuticals, Inc. 42
Merck KGaA 43
4SC AG 44
Genesis Research and Development Corporation Ltd. 45
Hollis-Eden Pharmaceuticals, Inc. 46
Active Biotech AB 47
Idera Pharmaceuticals, Inc. 48
Portola Pharmaceuticals, Inc. 49
Pharmacyclics, Inc. 50
Dynavax Technologies Corporation 51
Shenzhen Beike Biotechnology Co., Ltd. 52
Immupharma Plc 53
Neovacs SA 54
Argos Therapeutics, Inc. 55
Astion Pharma A/S 56
Vaccinex, Inc. 57
Theraclone Sciences, Inc. 58
Trillium Therapeutics Inc. 59
CBio Limited 60
Anthera Pharmaceuticals‚ Inc. 61
KYORIN Pharmaceutical Co., Ltd. 62
SuppreMol GmbH 63
NasVax Ltd. 64
Amplimmune, Inc. 65
Lycera Corp. 66
Zenyaku Kogyo Co., Ltd. 67
Systemic Lupus Erythematosus – Therapeutics Assessment 68
Assessment by Monotherapy Products 68
Assessment by Combination Products 69
Assessment by Route of Administration 70
Assessment by Molecule Type 73
Drug Profiles 76
Laquinimod - Drug Profile 76
Lupuzor - Drug Profile 78
AMG 811 - Drug Profile 79
AMG 557 - Drug Profile 81
Atacicept - Drug Profile 82
Rontalizumab - Drug Profile 85
LY2127399 - Drug Profile 86
Benlysta - Drug Profile 88
Sifalimumab - Drug Profile 90
IMO-3100 - Drug Profile 92
57-57 - Drug Profile 94
PCI-45261 - Drug Profile 96
PD-360324 - Drug Profile 97
PF-04236921 - Drug Profile 98
BT-063 - Drug Profile 100
IFNa-Kinoid - Drug Profile 101
AGS-009 - Drug Profile 103
AbGn-168H - Drug Profile 104
VX5 - Drug Profile 106
Triolex - Drug Profile 107
Interferon-Alpha - Drug Profile 109
CDP7657 - Drug Profile 110
A-623 - Drug Profile 112
AMP-110 - Drug Profile 114
ONX 0914 - Drug Profile 116
4SC-101 - Drug Profile 117
Zyrogen Targeting Antibody - Drug Profile 119
TTI-314 - Drug Profile 120
KRP-203 - Drug Profile 121
MEDI-546 - Drug Profile 123
MEDI570 - Drug Profile 124
Sirukumab - Drug Profile 126
DV-1179 - Drug Profile 127
ASF-1096 - Drug Profile 129
XToll - Drug Profile 130
N-Acetylcysteine - Drug Profile 132
PRT2607 - Drug Profile 133
Cyclosporine A - Drug Profile 134
Cyclophosphamide + Rituximab - Drug Profile 135
Rituximab + Cyclophosphamide - Drug Profile 136
SM101 - Drug Profile 137
RG105 + Prednisone - Drug Profile 139
IDEC-C2B8 - Drug Profile 140
Rapamune - Drug Profile 141
Epratuzumab - Drug Profile 142
Anti-ILT7 - Drug Profile 144
Rosuvastatin - Drug Profile 145
Prevenar + Pneumo23 - Drug Profile 146
Allogeneic Mesenchymal Stem Cells + Cyclophosphamide - Drug Profile 147
Influenza Vaccine - Drug Profile 148
Cyclophosphamide + rATG + Hematopoietic Stem Cell Transplantation - Drug Profile 149
Anti-aCD3 Mab - Drug Profile 150
PRT2070 - Drug Profile 152
Leukothera - Drug Profile 153
Bioenergetics Program - Drug Profile 154
Drug For Autoimmune Diseases - Drug Profile 155
AVP5 - Drug Profile 156
Cytokine-Like Proteins - Drug Profile 157
GSK2586184 - Drug Profile 158
AMG 729 - Drug Profile 159
IMO-8400 - Drug Profile 160
R-333 - Drug Profile 162
Systemic Lupus Erythematosus Therapeutics – Drug Profile Updates 163
Systemic Lupus Erythematosus Therapeutics – Discontinued Products 188
Systemic Lupus Erythematosus Therapeutics - Dormant Products 190
Systemic Lupus Erythematosus – Product Development Milestones 193
Featured News & Press Releases 193
Appendix 202
Methodology 202
Coverage 202
Secondary Research 202
Primary Research 202
Expert Panel Validation 202
Contact Us 203
Disclaimer 203

List of Tables
Number of Products Under Development for Systemic Lupus Erythematosus, H2 2012 14
Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, H2 2012 15
Number of Products under Development by Companies, H2 2012 17
Number of Products under Development by Companies, H2 2012 (Contd..1) 18
Number of Products under Development by Companies, H2 2012 (Contd..2) 19
Number of Products under Development by Companies, H2 2012 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H2 2012 22
Comparative Analysis by Late Stage Development, H2 2012 23
Comparative Analysis by Mid Clinical Stage Development, H2 2012 24
Comparative Analysis by Early Clinical Stage Development, H2 2012 25
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 26
Products under Development by Companies, H2 2012 27
Products under Development by Companies, H2 2012 (Contd..1) 28
Products under Development by Companies, H2 2012 (Contd..2) 29
Products under Development by Companies, H2 2012 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2012 31
Johnson & Johnson, H2 2012 32
F. Hoffmann-La Roche Ltd., H2 2012 33
Amgen Inc., H2 2012 34
Eli Lilly and Company, H2 2012 35
GlaxoSmithKline plc, H2 2012 36
Genentech, Inc., H2 2012 37
MedImmune LLC, H2 2012 38
Biotest AG, H2 2012 39
AbGenomics International, Inc., H2 2012 40
Human Genome Sciences, Inc., H2 2012 41
Pfizer Inc., H2 2012 42
Rigel Pharmaceuticals, Inc., H2 2012 43
Teva Pharmaceutical Industries Limited, H2 2012 44
UCB Group, H2 2012 45
Onyx Pharmaceuticals, Inc., H2 2012 46
Merck KGaA, H2 2012 47
4SC AG, H2 2012 48
Genesis Research and Development Corporation Ltd., H2 2012 49
Hollis-Eden Pharmaceuticals, Inc., H2 2012 50
Active Biotech AB, H2 2012 51
Idera Pharmaceuticals, Inc., H2 2012 52
Portola Pharmaceuticals, Inc., H2 2012 53
Pharmacyclics, Inc., H2 2012 54
Dynavax Technologies Corporation, H2 2012 55
Shenzhen Beike Biotechnology Co., Ltd., H2 2012 56
Immupharma Plc, H2 2012 57
Neovacs SA, H2 2012 58
Argos Therapeutics, Inc., H2 2012 59
Astion Pharma A/S, H2 2012 60
Vaccinex, Inc., H2 2012 61
Theraclone Sciences, Inc., H2 2012 62
Trillium Therapeutics Inc., H2 2012 63
CBio Limited, H2 2012 64
Anthera Pharmaceuticals‚ Inc., H2 2012 65
KYORIN Pharmaceutical Co., Ltd., H2 2012 66
SuppreMol GmbH, H2 2012 67
NasVax Ltd., H2 2012 68
Amplimmune, Inc., H2 2012 69
Lycera Corp., H2 2012 70
Zenyaku Kogyo Co., Ltd., H2 2012 71
Assessment by Monotherapy Products, H2 2012 72
Assessment by Combination Products, H2 2012 73
Assessment by Stage and Route of Administration, H2 2012 76
Assessment by Stage and Molecule Type, H2 2012 79
Systemic Lupus Erythematosus Therapeutics – Drug Profile Updates 167
Systemic Lupus Erythematosus Therapeutics – Discontinued Products 192
Systemic Lupus Erythematosus Therapeutics – Discontinued Products (Contd..1) 193
Systemic Lupus Erythematosus Therapeutics – Dormant Products 194
Systemic Lupus Erythematosus Therapeutics – Dormant Products (Contd..1) 195
Systemic Lupus Erythematosus Therapeutics – Dormant Products (Contd..2) 196

List of Figures
Number of Products under Development for Systemic Lupus Erythematosus, H2 2012 14
Products under Development for Systemic Lupus Erythematosus – Comparative Analysis, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 21
Late Stage Products, H2 2012 23
Mid Clinical Stage Products, H2 2012 24
Early Clinical Stage Products, H2 2012 25
Discovery and Pre-Clinical Stage Products, H2 2012 26
Assessment by Monotherapy Products, H2 2012 72
Assessment by Combination Products, H2 2012 73
Assessment by Route of Administration, H2 2012 74
Assessment by Stage and Route of Administration, H2 2012 75
Assessment by Molecule Type, H2 2012 77
Assessment by Stage and Molecule Type, H2 2012 78

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos